{"id":"NCT02939989","sponsor":"AbbVie","briefTitle":"Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study","officialTitle":"An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Combination With Sofosbuvir and Ribavirin in Chronic Hepatitis C (HCV) Infected Subjects Who Have Experienced Virologic Failure in AbbVie HCV Clinical Studies (MAGELLAN-3)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-11-21","primaryCompletion":"2021-05-07","completion":"2021-07-30","firstPosted":"2016-10-20","resultsPosted":"2022-05-04","lastUpdate":"2022-05-04"},"enrollment":33,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C Virus Infection"],"interventions":[{"type":"DRUG","name":"Sofosbuvir","otherNames":["SOVALDI"]},{"type":"DRUG","name":"Glecaprevir/Pibrentasvir","otherNames":["ABT-493/ABT-530","MAVYRET","MAVIRET"]},{"type":"DRUG","name":"Ribavirin","otherNames":[]}],"arms":[{"label":"Glecaprevir/Pibrentasvir + SOF + RBV for 12 weeks","type":"EXPERIMENTAL"},{"label":"Glecaprevir/Pibrentasvir + SOF + RBV for 16 weeks","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to evaluate the efficacy and safety of co-administration of glecaprevir (ABT-493)/pibrentasvir (ABT 530) plus sofosbuvir (SOF) plus ribavirin (RBV) in hepatitis C virus (HCV) genotype (GT) 1 - 6-infected participants (including non-cirrhotic, or cirrhotic with compensated cirrhosis participants) who had experienced virologic failure in an AbbVie parent clinical study.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)","timeFrame":"12 weeks after the last actual dose of study drug, Week 24 or Week 28 depending on the treatment regimen.","effectByArm":[{"arm":"Glecaprevir/Pibrentasvir + SOF + RBV for 12 Weeks","deltaMin":100,"sd":null},{"arm":"Glecaprevir/Pibrentasvir + SOF + RBV for 16 Weeks","deltaMin":96.4,"sd":null},{"arm":"Total","deltaMin":97,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":26,"countries":["United States","Australia","Canada","China","Germany","New Zealand","Russia","South Korea","Spain","Sweden","Switzerland","United Kingdom"]},"refs":{"pmids":["30857780"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":5},"commonTop":["PRURITUS","HEADACHE","DIZZINESS","FATIGUE","UPPER RESPIRATORY TRACT INFECTION"]}}